Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 3/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181713 | 1.00 | SYK (0.36) | SYKPDE10ARAF1PDE2AACP1 | |
| SCHEMBL30182002 | 0.91 | SYK (0.41) | SYKPDE10ARAF1ACP1MTOR | |
| SCHEMBL25005777 | 0.91 | SYK (0.41) | SYKPDE10ARAF1ACP1MTOR | |
| SCHEMBL23994827 | 0.91 | SYK (0.41) | SYKPDE10ARAF1ACP1MTOR | |
| SCHEMBL23995137 | 0.87 | RAF1 (0.32) | SYKRAF1MTORMDM2 | |
| SCHEMBL30224707 | 0.86 | PDE10A (0.35) | PDE10AMTORPPARD | |
| SCHEMBL30224302 | 0.86 | ABL1 (0.34) | SYKRAF1MTORCYP1A2METAP2 | |
| SCHEMBL23993110 | 0.86 | ABL1 (0.34) | SYKRAF1MTORCYP1A2METAP2 | |
| SCHEMBL23993837 | 0.86 | PDE10A (0.35) | PDE10AMTORPPARD | |
| SCHEMBL23992888 | 0.86 | PDE10A (0.34) | SYKPDE10ARAF1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | SYK 2578/4885PDE10A 484/4885RAF1 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.